Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veltuzumab - Immunomedics

Next Previous
Drug Profile

Veltuzumab - Immunomedics

Alternative Names: Anti-CD20 monoclonal antibody - Immunomedics; hA20; Humanised anti-CD20 monoclonal antibody; IMMU-106; Monoclonal antibody hA20; Monoclonal antibody IMMU-106

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Pemphigus; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Idiopathic thrombocytopenic purpura; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA as no subjects were enrolled (NCT01101581)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 12 Mar 2020 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top